Emibetuzumab, previously known as LY2875358, represents a unique therapeutic method in oncology, specifically targeting the HGFR tyrosine enzyme. This humanized immunoglobulin works by selectively binding to the HGF https://www.targetmol.com/compound/emibetuzumab